A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma

J Cancer Res Clin Oncol. 2016 Apr;142(4):845-8. doi: 10.1007/s00432-015-2079-y. Epub 2015 Dec 11.

Abstract

Purpose: Brooke-Spiegler syndrome (BSS, familial cylindromatosis) is a rare hereditary disease characterized by multiple tumors of the skin appendages predominantly located in the head and neck region, such as cylindromas, trichoepitheliomas, or spiradenomas. It is caused by an autosomal dominant mutation in the CYLD gene, mapped on chromosome 16q12-13. Association with secondary malignant neoplasms has been reported. Until now 51 different mutations in 73 families have been reported; 41 % of them constitute frameshift mutations, resulting in an interruption of the expression of the gene product CYLD. CYLD is a deubiquitinating enzyme and plays an important role in (NF)-κB pathway signaling, a central pathway for apoptosis regulation. Mutation-induced loss of function leads to constitutive activation of NF-κB.

Methods: Here, we report the case of a 48-year-old female patient diagnosed with an abdominal aggressive non-Hodgkin's lymphoma. The patient presented with multiple cylindromas of the capillitium. The patient's mother also has a mild form of late-onset cylindromas. Due to the typical clinical features indicating BSS, genotyping from peripheral blood was performed. A c.2465insAACA mutation in exon 17 of the CYLD gene, leading to a frameshift, was detected in the patient and in the patient's mother.

Results/conclusions: This is the first description of this hereditary mutation in exon 17 of the CYLD gene. There have been several reports on patients with CYLD mutations and different types of malignancies. However, a coincidence with aggressive non-Hodgkin's lymphoma has not been reported yet.

Keywords: Brooke–Spiegler syndrome; CYLD gene; Case report; Non-Hodgkin’s lymphoma; Novel mutation.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Neoplasms / complications
  • Abdominal Neoplasms / diagnosis*
  • Abdominal Neoplasms / therapy*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosomes, Human, Pair 16 / genetics
  • Deubiquitinating Enzyme CYLD
  • Drug Resistance, Neoplasm
  • Exons
  • Fatal Outcome
  • Female
  • Frameshift Mutation*
  • Humans
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / therapy*
  • Middle Aged
  • Mothers
  • Multiple Organ Failure
  • Neoplastic Syndromes, Hereditary / complications
  • Neoplastic Syndromes, Hereditary / diagnosis
  • Neoplastic Syndromes, Hereditary / genetics*
  • Nuclear Family
  • Positron-Emission Tomography
  • Radiotherapy, Adjuvant
  • Skin Neoplasms / complications
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / genetics*
  • Tomography, X-Ray Computed
  • Tumor Suppressor Proteins / genetics*

Substances

  • Tumor Suppressor Proteins
  • CYLD protein, human
  • Deubiquitinating Enzyme CYLD

Supplementary concepts

  • Familial cylindromatosis